EPCORITAMAB+GEMOX LEADS TO HIGH MRD‐NEGATIVITY RATES IN PATIENTS WITH RELAPSED/REFRACTORY DIFFUSE LARGE B‐CELL LYMPHOMA: AN UPDATED LONGITUDINAL MRD ANALYSIS | Publicación